Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS – Get Rating) saw a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 1,120,000 shares, a growth of 86.0% from the March 15th total of 602,200 shares. Approximately 1.8% of the company’s shares are short sold. Based on an average daily trading volume, of 545,600 shares, the short-interest ratio is presently 2.1 days.
Separately, StockNews.com assumed coverage on shares of Pieris Pharmaceuticals in a report on Thursday, March 31st. They set a “hold” rating on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Pieris Pharmaceuticals has an average rating of “Hold” and a consensus target price of $8.50.
Several large investors have recently added to or reduced their stakes in PIRS. Woodline Partners LP bought a new stake in shares of Pieris Pharmaceuticals in the 4th quarter valued at about $9,313,000. Marshall Wace LLP boosted its holdings in shares of Pieris Pharmaceuticals by 904.3% in the 4th quarter. Marshall Wace LLP now owns 2,203,777 shares of the biotechnology company’s stock valued at $8,330,000 after buying an additional 1,984,349 shares in the last quarter. Invesco Ltd. bought a new stake in shares of Pieris Pharmaceuticals in the 3rd quarter valued at about $7,764,000. Two Sigma Investments LP bought a new stake in shares of Pieris Pharmaceuticals in the 3rd quarter valued at about $6,036,000. Finally, Assenagon Asset Management S.A. boosted its holdings in shares of Pieris Pharmaceuticals by 358.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,475,778 shares of the biotechnology company’s stock valued at $5,578,000 after buying an additional 1,153,537 shares in the last quarter. Institutional investors and hedge funds own 51.91% of the company’s stock.
Pieris Pharmaceuticals (NASDAQ:PIRS – Get Rating) last issued its earnings results on Tuesday, March 1st. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.17. Pieris Pharmaceuticals had a negative net margin of 147.01% and a negative return on equity of 97.46%. The company had revenue of $8.44 million for the quarter, compared to analysts’ expectations of $4.91 million. On average, equities analysts expect that Pieris Pharmaceuticals will post -0.53 earnings per share for the current year.
Pieris Pharmaceuticals Company Profile (Get Rating)
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids.
- Get a free copy of the StockNews.com research report on Pieris Pharmaceuticals (PIRS)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- UiPath Stock is Nearing Rock Bottom Down Here
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.